JP2015503595A5 - - Google Patents

Download PDF

Info

Publication number
JP2015503595A5
JP2015503595A5 JP2014551505A JP2014551505A JP2015503595A5 JP 2015503595 A5 JP2015503595 A5 JP 2015503595A5 JP 2014551505 A JP2014551505 A JP 2014551505A JP 2014551505 A JP2014551505 A JP 2014551505A JP 2015503595 A5 JP2015503595 A5 JP 2015503595A5
Authority
JP
Japan
Prior art keywords
formula
heterocyclyl
compound
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014551505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503595A (ja
JP6122871B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2012/087606 external-priority patent/WO2013104257A1/zh
Publication of JP2015503595A publication Critical patent/JP2015503595A/ja
Publication of JP2015503595A5 publication Critical patent/JP2015503595A5/ja
Application granted granted Critical
Publication of JP6122871B2 publication Critical patent/JP6122871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014551505A 2012-01-12 2012-12-27 多環式化合物誘導体、それらの製造方法および医薬用途 Active JP6122871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210008286.9 2012-01-12
CN201210008286 2012-01-12
PCT/CN2012/087606 WO2013104257A1 (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2015503595A JP2015503595A (ja) 2015-02-02
JP2015503595A5 true JP2015503595A5 (enExample) 2016-01-28
JP6122871B2 JP6122871B2 (ja) 2017-04-26

Family

ID=48781054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551505A Active JP6122871B2 (ja) 2012-01-12 2012-12-27 多環式化合物誘導体、それらの製造方法および医薬用途

Country Status (14)

Country Link
US (1) US9139548B2 (enExample)
EP (1) EP2803664B1 (enExample)
JP (1) JP6122871B2 (enExample)
KR (1) KR102036547B1 (enExample)
CN (1) CN103429581B (enExample)
AU (1) AU2012365706B2 (enExample)
BR (1) BR112014016648B1 (enExample)
CA (1) CA2860353A1 (enExample)
MX (1) MX357780B (enExample)
RU (1) RU2621039C1 (enExample)
TW (1) TWI588136B (enExample)
UA (1) UA115975C2 (enExample)
WO (1) WO2013104257A1 (enExample)
ZA (1) ZA201404625B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592211B (zh) * 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104788412B (zh) * 2014-01-22 2017-02-15 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2016059042A1 (de) 2014-10-14 2016-04-21 Basf Se Verwendung von hexadeca-8,15-dienal als aromachemikalie
CN106478616B (zh) * 2015-08-27 2020-05-12 江苏恒瑞医药股份有限公司 一种gpr40激动剂的结晶形式及其制备方法
CN108236611A (zh) * 2016-12-27 2018-07-03 江苏恒瑞医药股份有限公司 两种化合物联合在制备治疗糖尿病药物中的用途
CN108236609B (zh) * 2016-12-27 2022-10-21 江苏恒瑞医药股份有限公司 一种gpr40激动剂药物组合物及其制备方法
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN114163426B (zh) 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0772610T3 (da) * 1994-07-22 2001-01-29 Byk Gulden Lomberg Chem Fab Dihydrobenzofuraner
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
EP1660428A1 (en) 2003-08-20 2006-05-31 Eli Lilly And Company Ppar modulators
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 3−(4−ベンジルオキシフェニル)プロパン酸誘導体
JP4875978B2 (ja) * 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
MX2008011615A (es) * 2006-03-14 2008-09-22 Amgen Inc Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos.
RS53230B (sr) * 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
EA022417B1 (ru) * 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
KR20110110286A (ko) 2009-01-30 2011-10-06 토야마 케미칼 컴퍼니 리미티드 N-아실 안트라닐산 유도체 또는 그 염
CN102421739A (zh) * 2009-04-22 2012-04-18 安斯泰来制药株式会社 羧酸化合物
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
CN102153553A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
US8299117B2 (en) * 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2015503595A5 (enExample)
RU2518073C2 (ru) Новое бициклическое гетероциклическое соединение
JP6122871B2 (ja) 多環式化合物誘導体、それらの製造方法および医薬用途
JP6717457B2 (ja) Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
JP5717445B2 (ja) (s)−エチル2−アミノ−3−(4−(2−アミノ−6−((r)−1−(4−クロロ−2−(3−メチル−1h−ピラゾール−1−イル)フェニル)−2,2,2−トリフルオロエトキシ)−ピリミジン−4−イル)フェニル)プロパノエートの固体形態
JP2016512823A5 (enExample)
EA018629B1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
JP2019014739A (ja) ハロゲン置換へテロ環化合物
US12077528B2 (en) Preparation method for deuterated macrocyclic compound
WO2014106606A1 (en) Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
TW202246218A (zh) 抗菌化合物
JP2021102645A (ja) メプリンアルファ及びベータの新規な阻害剤
CN105777544A (zh) 一种高光学纯度s-(+)-氟比洛芬酯的制备方法
JP2018522814A (ja) ピリジン化合物
CN108794517B (zh) 一种精氨酸酶抑制剂及其制备方法与用途
CN109134432B (zh) 氘代抗抑郁药物
CN116082259B (zh) 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂
CN112094219A (zh) 一种制备钾离子竞争性阻滞剂中间体的方法
ES2965041T3 (es) Composiciones para el tratamiento de la fibrosis pulmonar
US20240182485A1 (en) Process for preparing shp2 inhibitors
RU2832735C9 (ru) Антагонист эстрогенового рецептора
RU2832735C2 (ru) Антагонист эстрогенового рецептора
WO2007144128A1 (en) Pyrrolidine compounds as renin inhibitors
NZ736165A (en) Compositions for the treatment of kidney and/or liver disease
KR20260041099A (ko) Lp(a) 저하 활성을 갖는 피페리딘 화합물